or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    EXEL A Exelixis, Inc. -1.66
    BPMC A Blueprint Medicines Corporation 0.59
    GTHX A G1 Therapeutics, Inc. -2.57
    CRIS A Curis, Inc. -4.58
    ELVN A Enliven Therapeutics, Inc. 2.14
    DAWN B Day One Biopharmaceuticals, Inc. 6.06
    DCPH D Deciphera Pharmaceuticals, Inc. -3.33
    ACLX D Arcellx, Inc. 1.77
    PBYI D Puma Biotechnology Inc -3.48
    PRLD D Prelude Therapeutics Incorporated -17.70
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Receptors Biotechnology Breast Cancer Drugs Her2 Solid Tumors Treatment Of Breast Cancer Tyrosine Kinase Blastoma Gastrointestinal Gastrointestinal Stromal Tumor Glioblastoma Glioblastoma Multiforme Her2/Neu Lymphoma Mastocytosis Medicine Multiple Myeloma

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 9.67
    IDNA D iShares Genomics Immunology and Healthcare ETF 8.61
    BBP D BioShares Biotechnology Products Fund 6.1
    PBE D PowerShares Dynamic Biotech & Genome 5.84
    LABD B Direxion Daily S&P Biotech Bear 3X Shares 5.6
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare BBP to PBE Compare CNCR to BBP Compare IDNA to PBE

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        Apr 18 BPMC Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
        Apr 17 EXEL Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth
        Apr 17 GTHX G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
        Apr 16 EXEL Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
        Apr 15 ACLX Peering Into Arcellx's Recent Short Interest
        Apr 13 PRLD Several Insiders Invested In Prelude Therapeutics Flagging Positive News
        Apr 12 GTHX Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
        Apr 12 CRIS Top 3 Health Care Stocks That May Collapse In Q2
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Receptors Biotechnology Breast Cancer Drugs Her2 Solid Tumors Treatment Of Breast Cancer Tyrosine Kinase Blastoma Gastrointestinal Gastrointestinal Stromal Tumor Glioblastoma Glioblastoma Multiforme Her2/Neu Lymphoma Mastocytosis Medicine Multiple Myeloma
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags